Nov 132017
 

via American Academy of Ophthalmology

Study shows first-of-its kind gene therapy can restore vision to people with an inherited retinal disorder

Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.

Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.

Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.

LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient’s eyes.

Treatment doesn’t restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.

More than 200 patients with LCA have participated in gene therapy trials since 2007.

However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn’t obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.

Learn more: Genetic Treatment for Blindness May Soon be Reality

 

The Latest on: Gene therapy
  • China's Push Into Gene Therapy Targets Biotech's 1%
    on January 17, 2018 at 12:20 pm

    So far, CAR-T has shown extraordinary results. More than 60 percent of children treated with Kymriah were cured, while the rate of full remission for patients treated with Yescarta was more than half. The big problem is price. Kymriah costs $475,000 for a ... […]

  • Global Gene Therapy for Ovarian Cancer Pipeline Analysis Report 2018
    on January 16, 2018 at 8:18 am

    The "Gene Therapy for Ovarian Cancer - A Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering. The report covers the present scenario and the growth prospects of the gene therapy for ovarian cancer for 2018-2022. To ... […]

  • Gene Therapy Could Make Cancer Care More Unequal, and This Map Shows Why
    on January 15, 2018 at 10:53 am

    Two new cancer treatments have shown miraculous cures, but if you happen to live in Arkansas or Montana, or a handful of other rural states—let alone outside the U.S.—you’ll have to travel hundreds of miles to get them. And it’s by no means certain ... […]

  • Gene therapy comes of age
    on January 15, 2018 at 8:19 am

    1 Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD, USA. 2 Spark Therapeutics, Philadelphia, PA, USA. 3 Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 4 David Geffen School of Medicine, University of ... […]

  • At $850,000, price for new childhood blindness gene therapy four times too high, analysis says
    on January 14, 2018 at 11:48 am

    The $850,000 list price for a new medicine that treats a genetic form of childhood blindness is about four times too high for the value the drug provides, a nonprofit that studies the cost-effectiveness of new drugs said Friday, though it added that the ... […]

  • A newly approved gene therapy cures blindness -- but it costs nearly $1M
    on January 13, 2018 at 4:30 pm

    When Elizabeth Guardino brought home her newborn from the hospital, he seemed a healthy, bright-eyed boy. But three months later, she realized something was amiss – Christian was unable to track objects placed in front of him and had developed no facial ... […]

  • Drugmakers see a pricing blueprint in an $850,000 gene therapy
    on January 12, 2018 at 5:28 pm

    SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. Spark Therapeutics Inc (ONCE.O) plans to ... […]

  • Clashes Over the Future of Gene Therapy at the US' Biggest Biotech Meeting
    on January 12, 2018 at 12:15 pm

    For one dizzying, schmooze and booze-filled week every January, thousands of tech execs, VCs, and investment bankers grind their way through a four-day slog of panel sessions, poster presentations, networking meetings, and cocktail-drenched after-hours ... […]

  • Non-Profit Says $850,000 Gene Therapy Is At Least Twice As Expensive As It Should Be
    on January 12, 2018 at 11:13 am

    Earlier this month, Spark Therapeutics announced that its gene therapy Luxturna, for a rare form of blindness, would cost $850,000 a year. The price was below the $1 million-plus price tag many had expected, and was called fair by the chief medical officer ... […]

  • The coming of age of gene therapy: A review of the past and path forward
    on January 12, 2018 at 12:00 am

    After three decades of hopes tempered by setbacks, gene therapy—the process of treating a disease by modifying a person’s DNA—is no longer the future of medicine, but is part of the present-day clinical treatment toolkit. The Jan. 12 issue of the ... […]

via Google News and Bing News

Other Interesting Posts

Leave a Reply

%d bloggers like this: